Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...
GLP-1s are basically appetite’s off-switch: suddenly you’re “full” after three bites. Congrats on the smaller meals and ...
These will help you build a supportive foundation for the body.
Our work continues on behalf of TRICARE For Life beneficiaries. Learn the latest, and find out how to share your story with us.
Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...
The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the risk of serious kidney injury that can result from dehydration. This comes ...
The discussion surrounding GLP-1 medications needs to change to one that emphasizes science-based research and compassion.
Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...
One of the biggest risk factors for prediabetes is weight gain. Over the past several decades, rates of obesity have risen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback